Applied Radiation Oncology

Quality Assurance · Treatment Planning · Theranostics · Prostate Cancer

Phase 1 Trial Shows Promise for 212Pb-ADVC001 in Advanced Prostate Cancer

November 18, 2026 · News Release

Source: snmmi.org

Phase 1 Trial Shows Promise for 212Pb-ADVC001 in Advanced Prostate Cancer

A recent phase 1 trial published in The Journal of Nuclear Medicine’s Late-Breaking Fast Track has examined the safety and efficacy of a novel alpha-emitting radiopharmaceutical therapy (RPT), 212Pb-ADVC001, in patients with advanced prostate cancer. The study demonstrated that the treatment was well tolerated, with no dose-limiting toxicities reported.

Among the 22 patients treated with 212Pb-ADVC001, 80% experienced a reduction in prostate-specific antigen (PSA) levels by at least 50%, and the overall response rate was found to be 100%. These outcomes support the further clinical development of this therapeutic agent to address the substantial unmet needs in metastatic prostate cancer.

The application of prostate-specific membrane antigen (PSMA)–targeted RPT has become established for treating metastatic androgen pathway modulation-resistant prostate cancer (mAPM-R). While beta-emitting RPTs, such as 177Lu-PSMA-617, have shown improvements in overall survival and progression-free survival, resistance occurs in about one-third of patients, with many patients experiencing progression soon after treatment.

The study authors emphasized the limitations of current fixed dosing regimens, advocating for the development of novel treatment strategies that could optimize patient outcomes through more potent therapies and adaptable dosing schedules. The unique property of alpha-emitting RPTs is their delivery of concentrated radiation directly to cancer cells, with minimal impact on surrounding healthy tissue, which distinguishes them from beta emitters.

The TheraPb trial evaluated escalating doses of 60–200 MBq of 212Pb-ADVC001, administered at intervals ranging from every week to every six weeks. Participants included those with progressive mAPM-R, previously treated with both an androgen-receptor pathway inhibitor and taxane chemotherapy. Adverse events were closely monitored, with dry mouth and nausea being the most commonly reported, while serious adverse events were absent. Following favorable results, doses of 160 and 200 MBq have been recommended for phase 2 trials.

The median radiographic progression-free survival was noted to be 11.2 months, further highlighting the potential of this treatment. The authors suggested that the flexible dosing and favorable safety profile of 212Pb-ADVC001 warrant further investigation, including potential combination strategies with other anti-cancer agents.

The results underscore the innovative approach of alpha-emitting RPTs and their role in advancing treatment options for patients with advanced prostate cancer.

More in Quality Assurance